KROS

Insiders Updates

Wells Fargo initates Keros Therapeutics Inc (KROS) rating to an Overweight

Daniel Torres

Keros Therapeutics Inc’s recent filing unveils that its 10% Owner Pontifax Management 4 G.P. (20 unloaded Company’s shares for reported ...

Insiders Updates

The Attractiveness of Investing In Keros Therapeutics Inc (KROS) is Growing

Daniel Torres

Keros Therapeutics Inc’s recent filing unveils that its 10% Owner Pontifax Management 4 G.P. (20 unloaded Company’s shares for reported ...

Analysts Viewpoint

Wells Fargo analysts initates an Overweight rating for Keros Therapeutics Inc (KROS)

Samantha Gray

In a filing, Keros Therapeutics Inc revealed its 10% Owner Pontifax Management 4 G.P. (20 unloaded Company’s shares for reported ...

News

Analysts review Keros Therapeutics Inc’s rating

Roman Campbell

Keros Therapeutics Inc’s recently made public that its 10% Owner Pontifax Management 4 G.P. (20 unloaded Company’s shares for reported ...

Knox Daily
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.